Very recently, Sorafenib was shown to inhibit the IGFR in vitro (Yaktapour et al., 2013), which indicates that Raf comprises an uncertain drug target in the renal cancer cell lines tested with our approach. Here, IGF1R is linked to renal carcinoma.